Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic Treated Patients With AMI
This study evaluated differences between men and women in the presentation, management and outcome of heart attacks within the GUSTO V study.
Drug: fibrinolytic therapy or combination reduced fibrinolytic therapy
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic Treated Patients With AMI; Results of the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries - V Trial|
- Primary Outcome [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]All cause mortality at 30 days after randomization.
- Secondary Outcomes [ Time Frame: 7 days ] [ Designated as safety issue: Yes ]Incidence of myocardial reinfarction as evidenced by new electrocardiographic changes or elevation in cardiac enzyme levels with recurrent chest pain within 7 days, bleeding, stoke, intracranial hemorrhage (ICH), and complications of MI.
|Study Start Date:||June 2001|
|Study Completion Date:||October 2007|
|Primary Completion Date:||October 2007 (Final data collection date for primary outcome measure)|
The Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes (GUSTO) V trial examined a large, contemporary cohort of women and men with ST elevation myocardial infarction (STEMI) treated with fibrinolytic therapy. The objective of the present study was to evaluate sex differences in presentation, management and outcome in GUSTO V.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00245648
|United States, New York|
|NYU School of Medicine|
|New York, New York, United States, 10016|
|Principal Investigator:||Harmony Reynolds||NYU School of Medicine|